A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants
Completed · Phase 1 · NCT06895356
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $5,210
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 83
About the trial
- Sponsor
- AbbVie
- Tested
- Tavapadon (drug)
- Dates
- Started 2025-03-26; completion 2025-06-16
- Results posted
- Not yet
This study will assess the relative bioavailability of two different Oral formulations of tavapadon in healthy adult participants.
From ClinicalTrials.gov, last updated 2025-06-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $5,210 in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $5,210
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.